<DOC>
	<DOCNO>NCT02580552</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability investigational drug , MRG-106 , patient cutaneous T-cell lymphoma ( CTCL ) , mycosis fungoides subtype . MRG-106 inhibitor molecule call miR-155 find high level malignant T-cells many mycosis fungoides patient . miR-155 may important promote growth survival cancer cell . In Part A study , MRG-106 test injection directly CTCL lesion skin . In Part B study , MRG-106 give subcutaneous injection intravenous infusion . Other objective study measure absorption clearance MRG-106 blood , understand cell CTCL skin lesion respond expose MRG-106 .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study MRG-106 Patients With Cutaneous T Cell Lymphoma ( CTCL ) , MF Subtype</brief_title>
	<detailed_description>Study Design : - Part A : Cohorts 3-6 patient receive five intratumoral injection MRG-106 period 15 day follow-up additional 20 day , begin maximum deliverable intratumoral dose . Doses may decrease subsequent cohort determine minimum pharmacodynamically active dose . - Part B : Cohorts 3-6 patient receive six subcutaneous intravenous dos MRG-106 26 day , follow-up 56 day . The start dose select base tolerability MRG-106 determine Part A. Doses may escalate subsequent cohort determine maximum tolerate dose . - Patients Part B MRG-106 well tolerate may continue assign dose extension period study discretion investigator sponsor . - Any cohort Part A Part B may expand elucidate safety , tolerability , pharmacokinetics pharmacodynamic effect MRG-106 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Patients biopsy proven CTCL , MF subtype , clinical stage I , II , III , clinically stable stable treatment regimen â‰¥ 4 week Patients must refractory intolerant establish therapy condition Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Females must pregnant lactating . Women childbearing potential must use highly effective method contraception throughout study participation least 6 month follow last dose study drug Males must surgically sterile , abstinent , willing use acceptable doublebarrier method contraception treatment least 6 month last dose study drug Evidence visceral involvement relate CTCL History renal liver dysfunction evidence renal liver dysfunction screen History hematological abnormality ( e.g. , coagulopathy ) evidence hematological abnormality screen Positive time screen HIV , Hepatitis B surface antigen , Hepatitis C Prior malignancy within past 3 year ( allowance squamous cell basal cell carcinomas free margin excision ) Use investigational small molecule drug 30 day prior screen use investigational oligonucleotide biologic drug prior 90 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Cutaneous T-cell Lymphoma</keyword>
	<keyword>CTCL</keyword>
	<keyword>Mycosis Fungoides</keyword>
</DOC>